Table 2.
Multivariate cox proportional hazards regression model to predict progression-free survival from chemotherapy start by FGFR1 intensity level
| Variable | Level | Hazard ratio | 95% Hazard ratio confidence limits | Probability > Chi square test | |
|---|---|---|---|---|---|
| Treatment arm | Sorafenib vs. Sorafenib + interferon | 1.581 | 0.697 | 3.585 | 0.2725 |
| ECOG Status | 1 vs. 0 | 4.630 | 1.417 | 15.134 | 0.0112 |
| Anemia | Yes vs. No | 1.481 | 0.531 | 4.131 | 0.4535 |
| FGFR1 Intensity | (3 or 4) vs. 1 | 5.925 | 1.490 | 23.561 | 0.0115 |
| 2 vs. 1 | 4.209 | 1.126 | 15.725 | 0.0326 | |
ECOG, Eastern Cooperative Oncology Group; FGFR1, fibroblast growth factor receptor 1.